

## Purpose

The NIHR Comprehensive Clinical Research Network (CCRN) is one of eight NIHR Networks. They provide a world-class research infrastructure embedded in the NHS to support participation in high quality non commercial research and commercial studies across England. The Devolved Nations have similar arrangements in place to support clinical research.

The Non-Malignant Haematology Specialty Group is one of 26 Specialty Groups which provide national networks of topic-specific expertise. The group is helping to build research infrastructure within the NHS to support local haematologists and blood transfusion specialists throughout the UK become more actively involved in high quality research that benefits NHS patients. Specialty Groups are key to the success of the CCRN. They work at both national and local levels to ensure the successful delivery of research within their specialties. This means ensuring that studies are delivered to target and on time.

## What we offer

- Opportunities for healthcare professionals to become involved in haematology research
- Opportunities for existing researchers to access a network of skilled research support staff and wider patient populations.



## More information

Information about commercial research is available on the following website:

[www.crncc.nihr.ac.uk/Life+sciences+industry](http://www.crncc.nihr.ac.uk/Life+sciences+industry)

or by contacting the Industry Team:

[crncc.industry@nihr.ac.uk](mailto:crncc.industry@nihr.ac.uk)

Further information about what the Specialty Group and CCRN can offer you can be found in the booklet entitled "Comprehensive Clinical Research Network: An introduction". This booklet is available to download from the NIHR Clinical Research Network website:

[www.crncc.nihr.ac.uk/resources/leaflets+and+guides](http://www.crncc.nihr.ac.uk/resources/leaflets+and+guides)

Detailed information about Specialty Groups, including contact details for regional representatives can be found on the NIHR Clinical Research Network website:

[www.crncc.nihr.ac.uk/about\\_us/ccrn/specialty](http://www.crncc.nihr.ac.uk/about_us/ccrn/specialty)

## Get involved with the Non-Malignant Haematology Specialty Group

If you are in a region which has a local Non-Malignant Haematology Specialty Group Lead, please get in touch with them directly. If you are in a region which does not have a local Non-Malignant Haematology Lead, or for more information, please contact:

The CCRN Specialty Groups Team  
[crncc.specialty@nihr.ac.uk](mailto:crncc.specialty@nihr.ac.uk)  
0113 343 2314

Version 1 (October 2010)

# Non-Malignant Haematology

Working as part of the NIHR  
Comprehensive Clinical Research Network  
to promote and support world-class  
non-malignant haematology  
research in the NHS



## Non-Malignant Haematology

The remit of the Non-Malignant Haematology Specialty Group is to support a national portfolio of structured research studies relating to the pathogenesis, diagnosis, treatment and prevention of blood disorders. The Non-Malignant Haematology Specialty Group's portfolio includes:

- Haemoglobinopathy
- Haemostasis and thrombosis
- Blood transfusion
- Platelet disorders
- Stem cell research

Research studies of haematological cancers are supported by the NIHR National Cancer Research Network (NCRN) and the Non-Malignant Haematology Specialty Group works alongside the NCRN to support these studies.

The Non-Malignant Haematology Specialty Group is working with other stakeholders to ensure that new developments in the field of non-malignant haematology research are supported by an on going stream of clinically relevant research studies which can be feasibly delivered in the NHS setting.




## How we work

The CCRN is made up of 25 Comprehensive Local Research Networks (CLRN). Many of these CLRN have nominated Local Leads, as have the Devolved Nations, which make up the membership of the national Non-Malignant Haematology Specialty Group.

The national Group actively manages the research portfolio through regular progress review, identification of barriers to recruitment and actions to break these down. For instance CLRN can provide:

- Assistance with the R&D approval process
- Research nurses to consent patients into studies and perform study related procedures
- Support for services such as pharmacy, imaging and pathology
- Access to training opportunities.



Birmingham and the Black Country 1

Central and East London 2

Professor John Pasi (john.pasi@bartsandthelondon.nhs.uk)

Daniel Hart (Daniel.Hart@bartsandthelondon.nhs.uk)

Cheshire and Merseyside 3

Professor Cheng Hok Toh (c.h.toh@liv.ac.uk)

County Durham and Tees Valley 4

Dr Raymond Dang (ray.dang@stees.nhs.uk)

Cumbria and Lancashire 5

Essex and Hertfordshire 6

Greater Manchester 7

Hampshire and Isle of Wight 8

Kent and Medway 9

Dr Gillian Evans (gillian.evans@ekht.nhs.uk)

Leicestershire, Northamptonshire and Rutland 10

London (North West) 11

Professor Michael Laffan (m.laffan@imperial.ac.uk)

London (South) 12

Professor Ghulam Mufti (ghulam.mufti@kcl.ac.uk)

Norfolk and Suffolk 13

North and East Yorkshire and Northern Lincolnshire 14

Northumberland Tyne and Wear 15

Tina Biss (Tina.Biss@nuth.nhs.uk)

Peninsula 16

South Yorkshire 17

Surrey and Sussex 18

Thames Valley 19

Dr Simon Stanworth (simon.stanworth@nhsbt.nhs.uk)

Trent 20

West Anglia 21

Western 22

Andrew Mumford (Andrew.Mumford@ubht.swest.nhs.uk)

West Midlands (North) 23

West Midlands (South) 24

Professor Peter Rose (peter.rose@swh.nhs.uk)

West Yorkshire 25

Northern Ireland 26

Scotland 27

Professor Mike Greaves (m.greaves@abdn.ac.uk)

Wales 28

Dr Peter Collins (Chair) (peter.collins@wales.nhs.uk)